Aim: Cutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback